As­traZeneca gains EU nod for di­a­betes triple; Am­gen and Duke launch re­al-world PC­SK9 ob­ser­va­tion­al study

→ Weeks af­ter win­ning EU ap­proval to start mar­ket­ing da­pagliflozin as Forx­i­ga, As­traZeneca has racked up an­oth­er OK for a triplet com­bo in­volv­ing the SGLT2 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER